Fulltext

Long-Term Follow-Up of Cadaveric Breast Augmentation: What Can We Learn?

Modarressi, Ali ; Villard, Jean ; Tille, Jean-Christophe ; Pittet, Brigitte

In: Aesthetic Surgery Journal, 2015, vol. 35, no. 4, p. NP89-NP94

Aggiungi alla tua lista
    Titre
    • Long-Term Follow-Up of Cadaveric Breast Augmentation: What Can We Learn?
    Auteur
    • Modarressi, Ali. From the University Hospitals of Geneva, University of Geneva, Switzerland
    • Villard, Jean. From the University Hospitals of Geneva, University of Geneva, Switzerland
    • Tille, Jean-Christophe. From the University Hospitals of Geneva, University of Geneva, Switzerland
    • Pittet, Brigitte. From the University Hospitals of Geneva, University of Geneva, Switzerland
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Aesthetic Surgery Journal, 2015, vol. 35, no. 4, p. NP89-NP94. Oxford University Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:303360
    Summary
    Breast augmentation with cadaveric fat graft has long been available to patients in Eastern European countries, primarily in the Soviet Union and Eastern Germany. Most such procedures were performed from the 1970s to the 1990s. Although only a few case reports have been published, all of which involved complications that appeared several years after the procedure, it appears that, surprisingly, this nonvascularized and incompatible immunologic tissue is relatively well tolerated. We present the case of a 45-year-old Russian woman who underwent breast explantation, due to breast hardness and pain, 15 years after breast augmentation with cadaveric fat grafting. Through genetic studies, we confirmed that the host and the graft were HLA incompatible. Moreover, results of analyses excluded the possibility of an acute or chronic immunologic rejection by the host. We suppose that the early complications that often occur in such cases might result from a nonspecific, inflammatory reaction induced by acute tissue ischemia and necrosis, and the late local complications that occur years later may relate more to chronic inflammation, due to nonvascularized tissue, than to immunologic rejection. Therefore, we propose that different mechanisms may explain how this allogenic fat tissue could have been tolerated by the patient's immune system. We particularly underline the immunomodulatory effect of mesenchymal stem cells, which are abundant in adipose tissues. This characteristic of fat tissue should be investigated further to assess its potential in treating autoimmune diseases or reducing the likelihood of allograft rejections. Level of Evidence 5 Risk